| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/11/2009 | WO2009109341A1 Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 09/11/2009 | WO2009109334A1 (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain |
| 09/11/2009 | WO2009109270A1 5-oxo-2, 3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2 |
| 09/11/2009 | WO2009109259A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 09/11/2009 | WO2009109258A1 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 09/11/2009 | WO2009109230A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
| 09/11/2009 | WO2009109214A1 Process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, and composition thus obtained |
| 09/11/2009 | WO2009109132A1 A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases |
| 09/11/2009 | WO2009109109A1 Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors |
| 09/11/2009 | WO2009109071A1 Imidazopyridine compounds |
| 09/11/2009 | WO2009109035A1 Inhibitors of protein tyrosine kinase activity |
| 09/11/2009 | WO2009109029A1 Diquinolonium salt for the treatment of cancer |
| 09/11/2009 | WO2009109001A1 Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function |
| 09/11/2009 | WO2009108999A1 Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
| 09/11/2009 | WO2009091815A3 Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity |
| 09/11/2009 | WO2009090624A3 Chitosan gel for dermatological use, production method therefor and use of same |
| 09/11/2009 | WO2009088939A3 Compositions and methods for treating neurodegenerative diseases |
| 09/11/2009 | WO2009088673A3 Pharmaceutical composition |
| 09/11/2009 | WO2009087682A3 Stabilized injectable formulation of pregabalin |
| 09/11/2009 | WO2009087678A3 Nanodispersion |
| 09/11/2009 | WO2009087151A9 Polymorphic forms of moxifloxacin hydrochloride and processes for preparation thereof |
| 09/11/2009 | WO2009087148A3 Analgesic apatitic calcium-phosphate cement |
| 09/11/2009 | WO2009084835A3 Pharmaceutical composition for treatment and prevention of kidney diseases |
| 09/11/2009 | WO2009084834A3 Pharmaceutical composition for the treatment and prevention of cardiac disease |
| 09/11/2009 | WO2009083267A3 Steroid-17,17-lactol derivative, use thereof, and medicament containing said derivative |
| 09/11/2009 | WO2009082124A3 Pharmaceutical composition for the treatment and prevention of glaucoma |
| 09/11/2009 | WO2009081275A3 Antifolate compounds for the treatment of melanoma |
| 09/11/2009 | WO2009080762A3 Pharmaceutical composition |
| 09/11/2009 | WO2009080721A3 4 -aminopyrimidine derivatives as histamine h4 receptor antagonists |
| 09/11/2009 | WO2009080367A3 Specific inhibitors of pteridine reductase with antiparasitic action |
| 09/11/2009 | WO2009078981A3 Ppar-delta ligands and methods of their use |
| 09/11/2009 | WO2009071650A3 Amide compounds as boosters of antivirals |
| 09/11/2009 | WO2009071219A3 Oral dispersable tablet |
| 09/11/2009 | WO2009067541A3 Integrase inhibitors |
| 09/11/2009 | WO2009061889A4 Grape polyphenolics for platelet and bacterial control |
| 09/11/2009 | WO2009055506A9 Aminoflavone (nsc 686288) and combinations thereof for treating breast cancer |
| 09/11/2009 | WO2009053026A3 Process for producing carnosol from carnosic acid using hydrogen peroxide or peracids |
| 09/11/2009 | WO2009050198A3 Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases |
| 09/11/2009 | WO2009050197A3 Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor |
| 09/11/2009 | WO2009047826A3 Pharmaceutical composition comprising sucralphate and mesalazine |
| 09/11/2009 | WO2009038701A3 Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same |
| 09/11/2009 | WO2009037398A3 Foodstuff composition to improve digestibility of foodstuff lipids |
| 09/11/2009 | WO2009035430A3 Compositions and methods for bone formation and remodeling |
| 09/11/2009 | WO2009026446A3 Hdac inhibitors |
| 09/11/2009 | WO2009022899A8 Gel containing pirfenidone |
| 09/11/2009 | WO2009022893A8 Pharmaceutical composition combining an antimicrobial agent and a selective enkephalinase enzyme inhibitor, which can be used to control and treat acute bacterial diarrhoea |
| 09/11/2009 | WO2009007827A9 Novel diclofenac esters and uses thereof |
| 09/11/2009 | WO2009005338A8 Solid forms ult-i, ult-2 and ult-3 of emtricitabine |
| 09/11/2009 | WO2009001697A3 Microspheres having core/shell structure |
| 09/11/2009 | WO2008157740A3 Faah inhibitors |
| 09/11/2009 | WO2008097938A3 Indole polymorphs |
| 09/11/2009 | WO2008078109A3 Medicament |
| 09/11/2009 | WO2008067427A3 Insulin-like growth factor-1 receptor antagonists for modulation of weight and liposity |
| 09/11/2009 | WO2008001931A3 Fused cyclic compounds |
| 09/11/2009 | WO2007130927A3 Condensed tricyclic compounds as cgrp-receptor antagonists |
| 09/11/2009 | WO2007038428A3 Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds |
| 09/11/2009 | CA2754281A1 Combination therapy |
| 09/11/2009 | CA2753844A1 Compositions and methods for mucositis and oncology therapies |
| 09/11/2009 | CA2728855A1 Spiro derivatives of parthenin as novel anticancer agents |
| 09/11/2009 | CA2719115A1 Methods, dosage forms, and kits for administering ziprasidone without food |
| 09/11/2009 | CA2718402A1 Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 09/11/2009 | CA2718170A1 Boron-containing small molecules as anti-inflammatory agents |
| 09/11/2009 | CA2717900A1 Oral galenic formulation including ketorolac and b-complex vitamins, in which vitamin b6 is in an outer layer separated from the rest of the active principles |
| 09/11/2009 | CA2717825A1 Opthalmic composition |
| 09/11/2009 | CA2717816A1 Inhibitors of protein tyrosine kinase activity |
| 09/11/2009 | CA2717784A1 Method of producing a bran product |
| 09/11/2009 | CA2717753A1 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 09/11/2009 | CA2717741A1 Treatment of hearing and balance impairments with redox-active therapeutics |
| 09/11/2009 | CA2717736A1 Modulation of srpx2-mediated angiogenesis |
| 09/11/2009 | CA2717734A1 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
| 09/11/2009 | CA2717718A1 Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| 09/11/2009 | CA2717703A1 Minocycline compounds and methods of use thereof |
| 09/11/2009 | CA2717692A1 N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation |
| 09/11/2009 | CA2717604A1 Substituted sulfonamide derivatives |
| 09/11/2009 | CA2717511A1 Modulation of enzymatic structure, activity, and/or expression level |
| 09/11/2009 | CA2717509A1 Tyrosine kinase inhibitors |
| 09/11/2009 | CA2717478A1 Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof |
| 09/11/2009 | CA2717456A1 Modified release pharmaceutical compositions comprising mycophenolate and processes thereof |
| 09/11/2009 | CA2717453A1 2-aminoquinolines |
| 09/11/2009 | CA2717409A1 Improved anticancer treatments |
| 09/11/2009 | CA2717394A1 Novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptatke inhibitors |
| 09/11/2009 | CA2717388A1 Pim kinase inhibitors and methods of their use |
| 09/11/2009 | CA2717367A1 Novel 4-benzhydryl-tetrahydro-pyridine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 09/11/2009 | CA2717287A1 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes type 1 and 2 |
| 09/11/2009 | CA2717259A1 Controlled release drug delivery systems and pharmaceutical compositions formed therewith |
| 09/11/2009 | CA2717207A1 Methods of treatment employing prolonged continuous infusion of belinostat |
| 09/11/2009 | CA2717202A1 Leukotriene b4 inhibitors |
| 09/11/2009 | CA2717201A1 Macrolide compositions having improved taste and stability |
| 09/11/2009 | CA2717182A1 Process for preparing a pharmaceutical composition with anti-inflammatory and analgesic activity for administration via a patch for external use, and composition thus obtained |
| 09/11/2009 | CA2717173A1 Antiviral therapeutic agents |
| 09/11/2009 | CA2717172A1 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
| 09/11/2009 | CA2717171A1 Amino-quinoxaline and amino-quinoline compounds for use as adenosine a2a receptor antagonists |
| 09/11/2009 | CA2717138A1 Heterocyclic compound |
| 09/11/2009 | CA2717135A1 Combined use of cholestanol derivative |
| 09/11/2009 | CA2717117A1 Improved antitumoral treatments |
| 09/11/2009 | CA2717066A1 Crystalline phospholipid, method for its production and use in treating damaged tissue |
| 09/11/2009 | CA2717013A1 Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| 09/11/2009 | CA2717012A1 Use of flavonoide compounds for the propyhylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases |
| 09/11/2009 | CA2716977A1 Nicorandil carriers with enhanced stability |
| 09/11/2009 | CA2716952A1 Pyrazole [3,4-b] pyridine raf inhibitors |